Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Copeptin Testing During Pre-hospital Care in the Treatment of Chest Pain Suggestive of Acute Coronary Syndrome

Condition:   Chest Pain
Interventions:   Biological: Blood work in the ambulance;   Biological: Blood work upon arrival in the emergency room;   Biological: Blood work at 3 hours post-arrival in the emergency room
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified April 2014

Effect of Ticagrelor on Fractional Flow Reserve

Condition:   Fractional Flow Reserve
Interventions:   Drug: Ticagrelor;   Drug: Prasugrel or Clopidogrel
Sponsor:   University of Patras
Recruiting - verified April 2014

Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Patients After ACS

Conditions:   Acute Coronary Syndrome;   Smoking Cessation
Interventions:   Drug: Varenicline;   Drug: placebo
Sponsors:   Sheba Medical Center;   Hadassah Medical Organization;   Barzilai Medical Center
Not yet recruiting - verified April 2014

Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting

Condition:   Congestive Heart Failure
Intervention:   Device: Samsung LABGEO IVD-A20 CHF Test
Sponsors:   Samsung Electronics;   Nexus-Dx
Recruiting - verified April 2014

Fluid Status of Outpatients With Dyspnea

Conditions:   Dyspnea,;   Acute Heart Failure Syndrome;   Pulmonary Congestion
Sponsor:   Intersection Medical, Inc.
Not yet recruiting - verified April 2014

Impact of Nasal High-flow vs Venturi Mask Oxygen Therapy on Weaning Outcome: a Multicenter, Randomized, Controlled Trial

Conditions:   Weaning Failure;   Acute Respiratory Failure
Interventions:   Device: Optiflow (Fisher & Paykel Healthcare);   Device: Venturi mask
Sponsors:   Catholic University of the Sacred Heart;   Fisher and Paykel Healthcare
Not yet recruiting - verified April 2014

Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS

Condition:   CLOPIDOGREL, POOR METABOLISM of (Disorder)
Interventions:   Drug: genotyping guided therapy Ticagrelor, Clopidogrel;   Drug: standard therapy clopidogrel
Sponsor:   Chinese PLA General Hospital
Not yet recruiting - verified April 2014

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

Conditions:   Acute Lung Injury;   Sepsis
Intervention:   Drug: Ascorbic Acid
Sponsors:   Virginia Commonwealth University;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified April 2014

Systematic Follow-up of Patients Surviving an Episode of Acute Hypercapnic Respiratory Failure in the ICU

Condition:   Acute Hypercapnic Respiratory Failure
Sponsors:   Ligue Pulmonaire Genevoise;   University Hospital, Geneva
Recruiting - verified April 2014

Antiplatelet Therapy Following Stent Implantation

Conditions:   Acute Myocardial Infarction;   Coronary Syndrome;   Angina, Unstable
Sponsor:   Elpen Pharmaceutical Co. Inc.
Recruiting - verified January 2014

EYESHOT (EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian Coronary Care Units)

Condition:   Acute Coronary Syndromes
Sponsors:   Heart Care Foundation;   Centro Servizi ANMCO S.r.l.;   AstraZeneca
Completed - verified March 2014

Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease

Condition:   Sickle Cell Disease
Intervention:   Drug: Albuterol
Sponsor:   Duke University
Recruiting - verified March 2014

Tailored Antiplatelet Therapy Following PCI

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome;   Stenosis
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor;   Genetic: Retrospective Genotype testing;   Genetic: Prospective Genotype testing
Sponsors:   Mayo Clinic;   Applied Health Research Centre (AHRC), Toronto, Canada
Recruiting - verified April 2014

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified April 2014

Invasive vs Conservative Strategies in Non-ST-elevation Acute Coronary Syndrome and Comorbidities

Condition:   Acute Coronary Syndrome
Intervention:   Procedure: Coronary angiogram
Sponsors:   University of Valencia;   Instituto de Salud Carlos III
Active, not recruiting - verified April 2014

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Sponsor:   AstraZeneca
Recruiting - verified April 2014

ProspEctive First Evaluation in Chest Pain Trial

Conditions:   Chest Pain;   Shortness of Breath;   Suspected Acute Coronary Syndrome
Interventions:   Procedure: Coronary CT Angiography;   Procedure: Stress Test
Sponsor:   St. Luke's-Roosevelt Hospital Center
Recruiting - verified May 2012

The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury

Condition:   Lung Injury, Acute
Interventions:   Drug: Dose 1 GSK2586881;   Drug: Dose 2 GSK2586881;   Drug: Dose 3 GSK2586881;   Drug: Dose 4 GSK2586881;   Drug: Placebo (saline)
Sponsor:   GlaxoSmithKline
Recruiting - verified April 2014

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
Interventions:   Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
Sponsors:   New York University School of Medicine;   New York University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   Albany Stratton VA Medical Center;   Cedars-Sinai Medical Center;   Columbia University;   Duke University;   East Carolina University;   Emory University;   Harvard University;   Massachusetts General Hospital;   Montreal Heart Institute;   University of British Columbia;   University of Missouri, Kansas City;   Vanderbilt University
Recruiting - verified April 2014

Immune Globulin Subcutaenous (Human), 20%

Condition:   Primary Immunodeficiency Diseases (PID)
Interventions:   Biological: Immune Globulin Subcutaneous (Human), 20%;   Biological: Immune Globulin Intravenous (Human), 10%;   Biological: Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)
Sponsor:   Baxter Healthcare Corporation
Active, not recruiting - verified April 2014

RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol

Conditions:   Reflux;   Gastroesophageal Reflux Disease (GERD)
Sponsors:   Duke University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2014

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel

Condition:   Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Intervention:   Drug: Risk of selected safety events
Sponsor:   AstraZeneca
Recruiting - verified April 2014

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

Conditions:   Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
Interventions:   Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2014

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes
Interventions:   Drug: lenalidomide;   Biological: epoetin alfa;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified April 2014

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Conditions:   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions:   Drug: cyclophosphamide;   Drug: busulfan;   Drug: tacrolimus;   Drug: methotrexate;   Genetic: cytogenetic analysis;   Other: flow cytometry;   Other: pharmacological study;   Other: pharmacogenomic studies;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
Completed - verified April 2014

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts in Transformation
Interventions:   Drug: tipifarnib;   Procedure: clinical observation
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified April 2014

Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults

Conditions:   Chronic Lymphocytic Leukemia;   Graft vs Host Disease;   Leukemia;   Myelodysplastic Syndrome;   Myeloid Leukemia
Intervention:   Procedure: Blood cell transplantation
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 2014

Get CardioSmart

You're Invited